ChimeriVax-JE + STAMARIL

**ChimeriVax-JE + STAMARIL** is a combination vaccine co-administered for simultaneous active immunization against *Japanese encephalitis virus (JEV)* and *Yellow fever virus (YFV)*. - **ChimeriVax-JE (JE-CV):** A live-attenuated chimeric viral vaccine, genetically engineered using the YF-17D backbone with the prM/E genes of JEV SA14-14-2, providing immunity against Japanese encephalitis[1][3][4]. - **STAMARIL:** A live-attenuated Yellow fever vaccine containing the YFV 17D-204 strain, indicated for active immunization against yellow fever and robustly studied as highly immunogenic and protective[2]. - Mechanism of action involves both humoral (neutralizing antibodies) and cellular (T-cell) immune responses, including responses against nonstructural proteins in the chimeric vaccine[1][4]. - Developed for travelers or populations at risk for both diseases, clinical data supports simultaneous or sequential administration without increased risk or compromised immunogenicity[1]. - Developers: ChimeriVax-JE was developed by Acambis (now part of Sanofi), and STAMARIL is produced by Sanofi Pasteur[1][2].

Brand names

ImojevStamaril

Other names

JE-CVImojev (for ChimeriVax-JE; similar formulation in some markets)Yellow fever vaccine (STAMARIL component)Japanese encephalitis chimeric virus vaccine (ChimeriVax-JE component)